Repligen loses 20-year director Dawes as CEO transition gives way to renewal

Repligen is a bioprocessing-technology company rebuilding growth as biologics demand normalizes, with 2025 revenue growth and a completed CEO handoff to Olivier Loeillot. This is a governance transition, not an operating event. Karen Dawes is retiring from the board effective September 30 after more than 20 years of service. 〔0〕 The filing gives no replacement, committee reshuffle, strategic change, or financial impact, so it does not alter the company’s commercial or execution story. The main signal is that the leadership reset is continuing beyond the CEO role. Dawes explicitly links her timing to the completed CEO transition, saying she believes “now is the right time” to retire. 〔1〕 That makes this look more like planned board renewal than a loss of operating leadership, although her long tenure means some institutional knowledge leaves with her. Bottom line: This closes another chapter of Repligen’s leadership transition, but without a named successor or business consequence, it is largely a governance housekeeping event rather than a change to the investment story.